Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys

Journal of Steroid Biochemistry and Molecular Biology

Volumn 129, Issue 3-5, 2012, Pages 115-128

  Yamaoka, Masuo ^a   Hara, Takahito ^a   Hitaka, Takenori ^a   Kaku, Tomohiro ^a   Takeuchi, Toshiyuki ^a   Takahashi, Junzo ^a   Asahi, Satoru ^a   Miki, Hiroshi ^a   Tasaka, Akihiro ^a   Kusaka, Masami ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

17,20 Lyase; Androgen; Orteronel; Prostate cancer; Steroid hormone; TAK 700

Indexed keywords

ABIRATERONE; ALDOSTERONE; CORTICOSTERONE; CYTOCHROME P450C17; HYDROCORTISONE; KETOCONAZOLE; ORTERONEL; PRASTERONE; PROGESTERONE; STEROID 17,20 LYASE; STEROID 17ALPHA MONOOXYGENASE; TESTOSTERONE;

ADRENAL CELL; ANDROGEN SYNTHESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG MECHANISM; DRUG POTENCY; HAPLORHINI; HUMAN; HUMAN CELL; MALE; NONHUMAN; SINGLE DRUG DOSE; STEROID BLOOD LEVEL; STEROIDOGENESIS;

ADRENAL GLANDS; ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; CELL LINE, TUMOR; CELLS, CULTURED; DEHYDROEPIANDROSTERONE; ENZYME INHIBITORS; HUMANS; HYDROCORTISONE; IMIDAZOLES; KETOCONAZOLE; MACACA FASCICULARIS; MALE; NAPHTHALENES; ORCHIECTOMY; STEROID 17-ALPHA-HYDROXYLASE; STEROIDS; TESTOSTERONE;

MACACA FASCICULARIS;

EID: 84858228703     PISSN: 09600760     EISSN: 18791220     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2012.01.001     Document Type: Article

References (56)

1. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman Global cancer statistics CA Cancer J. Clin. 61 2011 69 90
2. C. Huggins, and C.V. Hodges Studies on prostate cancer. I. The effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res. 1 1941 293 297
3. G. Auclerc, E.C. Antoine, F. Cajfinger, A. Brunet-Pommeyrol, C. Agazia, and D. Khayat Management of advanced prostate cancer Oncologist 5 2000 36 44 (Pubitemid 30127543)
4. E.J. Small, S. Halabi, N.A. Dawson, W.M. Stadler, B.I. Rini, J. Picus, P. Gable, F.M. Torti, E. Kaplan, and N.J. Vogelzang Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583) J. Clin. Oncol. 22 2004 1025 1033 (Pubitemid 41095034)
5. I.F. Tannock, R. de Wit, W.R. Berry, J. Horti, A. Pluzanska, K.N. Chi, S. Oudard, C. Théodore, N.D. James, I. Turesson, M.A. Rosenthal, M.A. Eisenberger TAX 327 Investigators Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N. Engl. J. Med. 351 2004 1502 1512 (Pubitemid 39315317)
6. J. Edwards, N.S. Krishna, K.M. Grigor, and J.M.S. Bartlett Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer Br. J. Cancer 89 2003 552 556 (Pubitemid 37026442)
7. J. Holzbeierlein, P. Lal, E. LaTulippe, A. Smith, J. Satagopan, L. Zhang, C. Ryan, S. Smith, H. Scher, P. Scardino, V. Reuter, and W.L. Gerald Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance Am. J. Pathol. 164 2004 217 227 (Pubitemid 38364606)
8. C.D. Chen, D.S. Welsbie, C. Tran, S.H. Baek, R. Chen, R. Vessella, M.G. Rosenfeld, and C.L. Sawyers Molecular determinants of resistance to antiandrogen therapy Nat. Med. 10 2004 33 39 (Pubitemid 38524696)
9. S. Feng, Q. Tang, M. Sun, J.Y. Chun, C.P. Evans, and A.C. Gao Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2 Mol. Cancer Ther. 8 2009 665 671
10. J. Veldscholte, C. Ris-Stalpers, G.G. Kuiper, G. Jenster, C. Berrevoets, E. Claassen, H.C. van Rooij, J. Trapman, A.O. Brinkmann, and E. Mulder A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens Biochem. Biophys. Res. Commun. 173 1990 534 540
11. A.L. Schuurmans, J. Bolt, J. Veldscholte, and E. Mulder Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion J. Steroid Biochem. Mol. Biol. 37 1990 849 853
12. J.O. Elo, L. Kvist, K. Leinonen, V. Isomaa, P. Henttu, O. Lukkarinen, and P. Vihko Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol J. Clin. Endocrinol. Metab. 80 1995 3494 3500
13. T. Hara, J. Miyazaki, H. Araki, M. Yamaoka, N. Kanzaki, M. Kusaka, and M. Miyamoto Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome Cancer Res. 63 2003 149 153 (Pubitemid 36070433)
14. T. Yoshida, H. Kinoshita, T. Segawa, E. Nakamura, T. Inoue, Y. Shimizu, T. Kamoto, and O. Ogawa Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient Cancer Res. 65 2005 9611 9616 (Pubitemid 41541433)
15. J. Tan, Y. Sharief, K.G. Hamil, C.W. Gregory, D.Y. Zang, M. Sar, P.H. Gumerlock, R.W. deVere White, T.G. Pretlow, S.E. Harris, E.M. Wilson, J.L. Mohler, and F.S. French Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells Mol. Endocrinol. 11 1997 450 459 (Pubitemid 27147013)
16. G. Marcias, E. Erdmann, G. Lapouge, C. Siebert, P. Barthélé my, B. Duclos, J.P. Bergerat, J. Céraline, and J.E. Kurtz Identification of novel truncated androgen receptor (AR) mutants including unreported pre-mRNA splicing variants in the 22Rv1 hormone-refractory prostate cancer (PCa) cell line Hum. Mutat. 31 2010 74 80
17. S.M. Dehm, L.J. Schmidt, H.V. Heemers, R.L. Vessella, and D.J. Tindall Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance Cancer Res. 68 2008 5469 5477
18. R. Hu, T.A. Dunn, S. Wei, S. Isharwal, R.W. Veltri, E. Humphreys, M. Han, A.W. Partin, R.L. Vessella, W.B. Isaacs, G.S. Bova, and J. Luo Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer Cancer Res. 69 2009 16 22
19. Z. Guo, X. Yang, F. Sun, R. Jiang, D.E. Linn, H. Chen, H. Chen, X. Kong, J. Melamed, C.G. Tepper, H.J. Kung, A.M. Brodie, J. Edwards, and Y. Qiu A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth Cancer Res. 69 2009 2305 2313
20. M. Stanbrough, G.J. Bubley, K. Ross, T.R. Golub, M.A. Rubin, T.M. Penning, P.G. Febbo, and S.P. Balk Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer Cancer Res. 66 2006 2815 2825
21. R.J. Auchus The genetics pathophysiology, and management of human deficiencies of P450c17 Endocrinol. Metab. Clin. North Am. 30 2001 101 119 (Pubitemid 32381716)
22. D.S. Loose, P.B. Kan, M.A. Hirst, R.A. Marcus, and D. Feldman Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes J. Clin. Invest. 71 1983 1495 1499 (Pubitemid 13098940)
23. G. Attard, A.H. Reid, R. A'Hern, C. Parker, N.B. Oommen, E. Folkerd, C. Messiou, L.R. Molife, G. Maier, E. Thompson, D. Olmos, R. Sinha, G. Lee, M. Dowsett, S.B. Kaye, D. Dearnaley, T. Kheoh, A. Molina, and J.S. de Bono Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer J. Clin. Oncol. 27 2009 3742 3748
24. J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R.J. Jones, O.B. Goodman Jr., F. Saad, J.N. Staffurth, P. Mainwaring, S. Harland, T.W. Flaig, T.E. Hutson, T. Cheng, H. Patterson, J.D. Hainsworth, C.J. Ryan, C.N. Sternberg, S.L. Ellard, A. Fléchon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C.M. Haqq, H.I. Scher COU-AA-301 Investigators Abiraterone and increased survival in metastatic prostate cancer N. Engl. J. Med. 364 2011 1995 2005
25. T. Kaku, T. Hitaka, A. Ojida, N. Matsunaga, M. Adachi, T. Tanaka, T. Hara, M. Yamaoka, M. Kusaka, T. Okuda, S. Asahi, S. Furuya, and A. Tasaka Discovery of orteronel (TAK-700) a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer Bioorg. Med. Chem. 19 2011 6383 6399
26. A.J. Conley, J.C. Pattison, and I.M. Bird Variations in adrenal androgen production among (nonhuman) primates Semin. Reprod. Med. 22 2004 311 326 (Pubitemid 40030081)
27. D.H. Abbott, and I.M. Bird Nonhuman primates as models for human adrenal androgen production: function and dysfunction Rev. Endocr. Metab. Disord. 10 2009 33 42
28. A.C. Swart, N.W. Kolar, N. Lombard, J.I. Mason, and P. Swart Baboon cytochrome P450 17α-hydroxylase/17,20-lyase (CYP17): characterization of the adrenal microsomeal and cloned enzymes Eur. J. Biochem. 269 2002 5608 5616 (Pubitemid 35365549)
29. W. Arlt, J.W. Martens, M. Song, J.T. Wang, R.J. Auchus, and W.L. Miller Molecular evolution of adrenarche: structural and functional analysis of P450c17 from 4 primate species Endocrinology 143 2002 4665 4672 (Pubitemid 35397608)
30. l7,20-lyase): potential agents for the treatment of prostatic cancer J. Med. Chem. 38 1995 2463 2471
31. R.J. Schiebinger, B.D. Albertson, F.G. Cassorla, D.W. Bowyer, G.W. Geelhoed, G.B. Cutler Jr., and D.L. Loriaux The developmental changes in plasma adrenal androgens during infancy and adrenarche are associated with changing activities of adrenal microsomal 17-hydroxylase and 17,20-desmolase J. Clin. Invest. 67 1981 1177 1182 (Pubitemid 11090559)
32. B.D. Albertson, D.D. Brandon, G.P. Chrousos, and D.L. Loriaux Adrenal 11-hydroxylase activity in a hypercortisolemic New World primate: adaptive intra-adrenal changes Steroids 49 1987 497 505
33. T. Imai, H. Globerman, J.M. Gertner, N. Kagawa, and M.R. Waterman Expression and purification of functional human 17 alpha-hydroxylase/17,20-lyase (P450c17) in Escherichia coli. Use of this system for study of a novel form of combined 17 alpha-hydroxylase/17,20-lyase deficiency J. Biol. Chem. 268 1993 19681 19689 (Pubitemid 23270759)
34. R.S. Rosenfeld, B.J. Rosenberg, D.K. Fukushima, and L. Hellman 24-Hour secretory pattern of dehydroisoandrosterone and dehydroisoandrosterone sulphate J. Clin. Endocrinol. Metab. 40 1975 850 855
35. D.T. Krieger, W. Allen, F. Rizzo, and H.P. Krieger Characterization of the normal temporal pattern of plasma corticosteroid levels J. Clin. Endocrinol. Metab. 32 1971 266 284
36. T.F. Gallagher, K. Yoshida, H.D. Roffwarg, D.K. Fukushima, E.D. Weitzman, and L. Hellman ACTH and cortisol secretory patterns in man J. Clin. Endocrinol. Metab. 36 1973 1058 1068
37. M. Okamoto, C. Setaishi, K. Nakagawa, Y. Horiuchi, K. Moriya, and S. Itoh Diurnal variations in the levels of plasma and urinary androgens J. Clin. Endocrinol. Metab. 32 1971 846 851
38. J.M. Davidson, C. Cheung, E.R. Smith, and P. Johnston Feedback regulation of gonadotrophins in the male Adv. Biosci. 10 1973 63 72
39. S.N. Freeman, W.I. Mainwaring, and B.J. Furr A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen Casodex (ICI 176,334) Br. J. Cancer 60 1989 664 668 (Pubitemid 19275727)
40. V.J. Cobb, B.C. Williams, J.I. Mason, and S.W. Walker Forskolin treatment directs steroid production towards the androgen pathway in the NCI-H295R adrenocortical tumour cell line Endocr. Res. 22 1996 545 550 (Pubitemid 26424375)
41. S. Nakajin, and P.E. Hall Microsomal cytochrome P-450 from neonatal pig testis. Purification and properties of A C21 steroid side-chain cleavage system (17 alpha-hydroxylase-C17,20 lyase) J. Biol. Chem. 256 1981 3871 3876
42. R.J. Auchus, and M.K. Gupta Towards a unifying mechanism for CYP17 mutations that cause isolated 17,20-lyase deficiency Endocr. Res. 28 2002 443 447 (Pubitemid 36042499)
43. R.J. Auchus, T.C. Lee, and W.L. Miller Cytochrome b5 augments the 17,20-lyase activity of human P450c17 without direct electron transfer J. Biol. Chem. 273 1998 3158 3165 (Pubitemid 28109723)
44. S. Mapes, C.J. Corbin, A. Tarantal, and A. Conley The primate adrenal zona reticularis is defined by expression of cytochrome b5 17alpha-hydroxylase/ 17,20-lyase cytochrome P450 (P450c17) and NADPH-cytochrome P450 reductase (reductase) but not 3beta-hydroxysteroid dehydrogenase/delta5-4 isomerase (3beta-HSD) J. Clin. Endocrinol. Metab. 84 1999 3382 3385 (Pubitemid 30646971)
45. M. Yamaoka, T. Hara, H. Miki, T. Hitaka, T. Kaku, N. Kawaguchi, H. Yamasaki, T. Takeuchi, A. Tasaka, and M. Kusaka TAK-700: an inhibitor of 17,20-lyase Proceedings of the 101st Annual Meeting of the American Association for Cancer Research 2010 April 17-21, Washington, DC 2010 AACR Philadelphia, PA (Abstract no. DD01-3)
46. R. Dreicer, D.B. Agus, G.R. MacVicar, J. Wang, D. MacLean, and W.M. Stadler Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostate cancer: a phase I/II, open-label study J. Clin. Oncol. 28 15s 2010 (Abstract no. 3084)
47. E. Folkerd, G. Attard, D. Dearnaley, J. Hunt, G. Maier, A. Molina, D. Olmos, N. Oomen, C. Parker, A. Reid, E. Thompson, J. De Bono1, and M. Dowsett Abiraterone acetate: the novel application of a CYP450c17 inhibitor to the treatment of both prostate and breast cancer Endocr. Abstr. 19 2009 180
48. C.J. Ryan, M.R. Smith, L. Fong, J.E. Rosenberg, P. Kantoff, F. Raynaud, V. Martins, G. Lee, T. Kheoh, J. Kim, A. Molina, and E.J. Small Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy J. Clin. Oncol. 28 2010 1481 1488
49. R.B. Montgomery, E.A. Mostaghel, R. Vessella, D.L. Hess, T.F. Kalhorn, C.S. Higano, L.D. True, and P.S. Nelson Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth Cancer Res. 68 2008 4447 4454
50. J.A. Locke, E.S. Guns, A.A. Lubik, H.H. Adomat, S.C. Hendy, C.A. Wood, S.L. Ettinger, M.E. Gleave, and C.C. Nelson Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer Cancer Res. 68 2008 6407 6415
51. H. Fuse, S. Korenaga, M. Sakari, T. Hiyama, T. Ito, K. Kimura, and S. Kato Non-steroidal antiandrogens act as AF-1 agonists under conditions of high androgen-receptor expression Prostate 67 2007 630 637 (Pubitemid 46685283)
52. D.C. Danila, M.J. Morris, J.S. de Bono, C.J. Ryan, S.R. Denmeade, M.R. Smith, M.E. Taplin, G.J. Bubley, T. Kheoh, C. Hagg, A. Molina, A. Anand, M. Koscuiszka, S.M. Larson, L.H. Schwartz, M. Fleisher, and H.I. Scher Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J. Clin. Oncol. 28 2010 1496 1501
53. A.H. Reid, G. Attard, D.C. Danila, N.B. Oommen, D. Olmos, P.C. Fong, L.R. Molife, J. Hunt, C. Messiou, C. Parker, D. Dearnaley, J.F. Swennenhuis, L.W. Terstappen, G. Lee, T. Kheoh, A. Molina, C.J. Ryan, E. Small, H.I. Scher, and J.S de Bono Significant sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate J. Clin. Oncol. 28 2010 1489 1495
54. J.E. Ang, D. Olmos, and J.S. de Bono CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer Br. J. Cancer 100 2009 671 675
55. G. Attard, A.H. Reid, D. Olmos, and J.S. de Bono Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven Cancer Res. 69 2009 4937 4940
56. S. Shah, and C. Ryan Abiraterone acetate for castration resistant prostate cancer Expert Opin. Invest. Drugs 19 2010 563 570